Lifespans are poor for these patients, with many failing to live for a year. But research hints that the prognosis in AIDS-NHL patients on HAART may actually be better than in the non-HIV population, she said.
A trial published in September 2020, in fact, reports that 87% of 15 patients with AIDS-associated plasmablastic lymphoma survived for at least one year on the EPOCH regimen. Overall, the study found that “people with a collection of HIV-associated lymphomas were doing well overall with the EPOCH backbone,” Reid explained.
Reid reported no relevant disclosures.
